“Finalizing the transaction, we now hold the rights of Quillivant XR for the entire North American marketing. Quillivant XR is methylphenidate hydrochloride used for the extended release of CII, the oral-suspension that is the first single-daily liquid oral dose for treating ADHD”, said Pfizer. Pfizer also added that from January 2013, the CII drug would be made available over the counter with prescription post the announcement on the drug approval by the US Food and Drug Administration (FDA) in September.
Quivillant XR (CII) is a highly controlled medication since misuse of the drug may cause harm to the patient and while also increasing addiction risks. It is highly recommended by health experts that the drug is stored in a safe place. CII is a mind stimulator that helps decreasing impulsive and hyperactive behavior of the patient to increase attention span.